This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts
by Zacks Equity Research
Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter.
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Markets Mostly Dip Red Late in Regular Trading
by Mark Vickery
After the closing bell, Zoom shares are -4% and HIMS are trading -17% lower on Q4 earnings results.
Hims & Hers Health, Inc. (HIMS) Lags Q4 Earnings Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -8.33% and 2.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $42.20, representing a +0.84% change from its previous close.
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
by Urmimala Biswas
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Hims & Hers Health, Inc. (HIMS) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.
Brian's Big Idea: Healthcare Stocks
by Brian Bolan
Look at 3 healthcare stocks and the Healthcare Innovators service at Zacks.com.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $25.90, moving +1.93% from the previous trading session.
Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FNY
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $26.90, moving +1.01% from the previous trading session.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run
by Debanjana Dey
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
HIMS Stock Surges 43% in a Month: Will the Uptrend Continue Further?
by Indrajit Bandyopadhyay
Hims & Hers Health sees robust 2024 growth with $401.6-million Q3 revenues (+77% YoY), 2M+ subscribers and plans to exceed $1.5B in revenues in 2024. Where will the stock go?